📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. (2023)

First Author: Upasani V

Attributed to: Broadly neutralising antibodies after vaccination funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciad368

PubMed Identifier: 37338118

Publication URI: http://europepmc.org/abstract/MED/37338118

Type: Journal Article/Review

Volume: 77

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 7

ISSN: 1058-4838